Biogen Idec (NQ: BIIB )

266.15 -1.76 (-0.66%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

7 Healthcare Stocks to Buy for Long-Term Growth and Stability

March 21, 2023

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.

Via InvestorPlace

Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit

March 21, 2023

Via Benzinga

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo

March 20, 2023

Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.

Via Benzinga

Should You Buy Biogen Before a Big July Decision?

March 19, 2023

Biogen stock has dropped about 40% from its record high.

Via The Motley Fool

Price Over Earnings Overview: Biogen

March 17, 2023

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest

March 17, 2023

Via Benzinga

Biogen's Debt Overview

March 15, 2023

Via Benzinga

1 Reason to Buy Biogen Stock, and 1 Reason to Sell

March 14, 2023

It could be a make or break year for the biotech.

Via The Motley Fool

Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval

February 28, 2023

The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys.

Via Investor's Business Daily

Biogen (BIIB) Q4 2022 Earnings Call Transcript

February 15, 2023

BIIB earnings call for the period ending December 31, 2022.

Via The Motley Fool

Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year

March 16, 2023

Via Benzinga

Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments

March 16, 2023

Via Benzinga

Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity

March 14, 2023

Via Benzinga

Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone

March 13, 2023

Via Benzinga

Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed

March 09, 2023

The company is definitively closing the door on solanezumab.

Via Investor's Business Daily

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock

March 09, 2023

Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule.

Via InvestorPlace

Why Biogen Stock Is Falling Today

February 15, 2023

Via Benzinga

Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales

February 15, 2023

The company expects "modest" Leqembi sales, but there's a caveat.

Via Investor's Business Daily

Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8

March 08, 2023

Looking for a bottom in wave {v} to then look for longs.

Via Talk Markets

Why Shares of Anavex Life Sciences Rose 12.4% in February

March 06, 2023

The company's first-quarter earnings report detailed positive news regarding its pipeline.

Via The Motley Fool

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment

March 06, 2023

Via Benzinga

What Does Biogen's Debt Look Like?

March 02, 2023

Shares of Biogen Inc. (NASDAQ:BIIB) moved lower by 7.52% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its...

Via Benzinga

Peering Into Biogen's Recent Short Interest

March 01, 2023

Biogen's (NASDAQ:BIIB) short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that...

Via Benzinga

Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit

February 27, 2023

The FDA is set to review the company's neurological drug by Tuesday.

Via Investor's Business Daily

Why Reata Pharmaceuticals Shares Are Falling Monday?

February 27, 2023

According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately.

Via Benzinga

Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca

February 25, 2023

Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...

Via Talk Markets

Analyst Initiates Coverage of GE Healthcare, Says' Path To Greatness Well-Paved'

February 17, 2023

Via Benzinga

Biogen Beats Q4 Earnings & Sales Estimates, Stock Up

February 15, 2023

Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05.

Via Talk Markets

Cisco, Analog Devices And 3 Stocks To Watch Heading Into Wednesday

February 15, 2023

With US futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

US Stocks Settle Mixed; Investor Optimism Improves

February 15, 2023

The CNN Money Fear and Greed index showed an improvement in the overall sentiment among US investors.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.